Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (101-110 of 171) with videos related to

Pageof 18
Sort By:
Circulation|April 17, 2002
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failureKarl Swedberg, Michael R Bristow, Jay N Cohn, et al.
Journal of Cardiac Failure|July 3, 2007
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFTJay N Cohn, S William Tam, Inder S Anand, et al.
European Journal of Preventive Cardiology|September 22, 2021
Early cardiovascular structural and functional abnormalities as a guide to future morbid eventsDaniel A Duprez, Sue Duval, Lynn Hoke, et al.
American Journal of Hypertension|April 3, 2003
Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular eventsElizabeth Grey, Chris Bratteli, Stephen P Glasser, et al.
Journal of the American Society of Hypertension : JASH|April 23, 2010
Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertensionMasood Gilani, Daniel R Kaiser, Christopher W Bratteli, et al.
Journal of the American College of Cardiology|September 13, 2008
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)Serge Masson, Roberto Latini, Inder S Anand, et al.
Journal of the American Society of Hypertension : JASH|July 2, 2011
Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observationsDaniel A Duprez, Natalia Florea, Wei Zhong, et al.
American Heart Journal|July 12, 2011
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT)Judith E Mitchell, S William Tam, Kamini Trivedi, et al.
Lancet (London, England)|July 28, 2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialInder Anand, John McMurray, Jay N Cohn, et al.
Journal of Cardiac Failure|November 11, 2008
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure TrialJalal K Ghali, S William Tam, Michael L Sabolinski, et al.
Pageof 18

Showing results (101-110 of 171) with videos related to

Sort By:
Pageof 18
Circulation|April 17, 2002
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failureKarl Swedberg, Michael R Bristow, Jay N Cohn, et al.
Journal of Cardiac Failure|July 3, 2007
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFTJay N Cohn, S William Tam, Inder S Anand, et al.
European Journal of Preventive Cardiology|September 22, 2021
Early cardiovascular structural and functional abnormalities as a guide to future morbid eventsDaniel A Duprez, Sue Duval, Lynn Hoke, et al.
American Journal of Hypertension|April 3, 2003
Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular eventsElizabeth Grey, Chris Bratteli, Stephen P Glasser, et al.
Journal of the American Society of Hypertension : JASH|April 23, 2010
Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertensionMasood Gilani, Daniel R Kaiser, Christopher W Bratteli, et al.
Journal of the American College of Cardiology|September 13, 2008
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)Serge Masson, Roberto Latini, Inder S Anand, et al.
Journal of the American Society of Hypertension : JASH|July 2, 2011
Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observationsDaniel A Duprez, Natalia Florea, Wei Zhong, et al.
American Heart Journal|July 12, 2011
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT)Judith E Mitchell, S William Tam, Kamini Trivedi, et al.
Lancet (London, England)|July 28, 2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialInder Anand, John McMurray, Jay N Cohn, et al.
Journal of Cardiac Failure|November 11, 2008
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure TrialJalal K Ghali, S William Tam, Michael L Sabolinski, et al.
Pageof 18